NASDAQ:IPHA Innate Pharma (IPHA) Stock Price, News & Analysis → Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad) Buy IPHA with Qtrade Free IPHA Stock Alerts $2.43 -0.11 (-4.33%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$2.38▼$2.4350-Day Range$2.28▼$2.8852-Week Range$1.81▼$3.57Volume3,106 shsAverage Volume10,446 shsMarket Capitalization$196.49 millionP/E RatioN/ADividend YieldN/APrice Target$9.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Innate Pharma alerts: Email Address Innate Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside301.2% Upside$9.75 Price TargetShort InterestBearish0.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.04 out of 5 starsMedical Sector556th out of 908 stocksBiological Products, Except Diagnostic Industry88th out of 149 stocks 3.5 Analyst's Opinion Consensus RatingInnate Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInnate Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.10% of the outstanding shares of Innate Pharma have been sold short.Short Interest Ratio / Days to CoverInnate Pharma has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Innate Pharma has recently increased by 5.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInnate Pharma does not currently pay a dividend.Dividend GrowthInnate Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPHA. Previous Next 2.5 News and Social Media Coverage News SentimentInnate Pharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Innate Pharma this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innate Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.16% of the stock of Innate Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Innate Pharma are expected to grow in the coming year, from ($0.94) to ($0.84) per share.Price to Book Value per Share RatioInnate Pharma has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyNew Trump BombshellI believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… Click here to see my 2024 election prediction. About Innate Pharma Stock (NASDAQ:IPHA)Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Read More IPHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPHA Stock News HeadlinesMay 1, 2024 | americanbankingnews.comShort Interest in Innate Pharma S.A. (NASDAQ:IPHA) Grows By 5.7%April 15, 2024 | businesswire.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024May 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 15, 2024 | businesswire.comInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsApril 10, 2024 | businesswire.comInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateApril 9, 2024 | finance.yahoo.comInnate Pharma Announces Its Participation in Upcoming Investor ConferenceApril 9, 2024 | businesswire.comInnate Pharma Announces Its Participation in Upcoming Investor ConferenceApril 5, 2024 | finance.yahoo.comInnate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-FMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 5, 2024 | businesswire.comInnate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-FMarch 23, 2024 | seekingalpha.comInnate Pharma S.A. (IPHA) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | finance.yahoo.comInnate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Reports Full Year 2023 Financial Results and Business UpdateMarch 21, 2024 | businesswire.comInnate Pharma Reports Full Year 2023 Financial Results and Business UpdateMarch 19, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Announces Its Participation to Upcoming Investor ConferenceMarch 19, 2024 | businesswire.comInnate Pharma Announces Its Participation to Upcoming Investor ConferenceMarch 14, 2024 | businesswire.comInnate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial ResultsMarch 6, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024March 6, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's LymphomaMarch 6, 2024 | finance.yahoo.comInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s LymphomaMarch 6, 2024 | businesswire.comInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024March 6, 2024 | businesswire.comInnate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's LymphomaFebruary 21, 2024 | businesswire.comInnate Pharma Announces Its Participation to Upcoming Investor ConferenceJanuary 12, 2024 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of January 1, 2024January 4, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical ProgramJanuary 4, 2024 | finanznachrichten.deInnate Pharma SA: Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive BoardJanuary 4, 2024 | finance.yahoo.comInnate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive BoardSee More Headlines Receive IPHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IPHA CUSIPN/A CIK1598599 Webwww.innate-pharma.com Phone33-4-30-30-30-30FaxN/AEmployees179Year FoundedN/APrice Target and Rating Average Stock Price Target$9.75 High Stock Price Target$11.50 Low Stock Price Target$8.00 Potential Upside/Downside+302.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.60 Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual Sales$66.71 million Price / Sales2.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book3.51Miscellaneous Outstanding Shares80,860,000Free Float55,074,000Market Cap$195.68 million OptionableNot Optionable Beta0.38 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Herve Brailly Ph.D. (Age 63)Co-Founder, Interim CEO & Chairman of Executive Board Mr. Yannis Morel Ph.D. (Age 51)Executive VP, COO & Member of Executive Board Comp: $382.41kDr. François Romagné Ph.D. (Age 60)Founder Mr. Eric Vivier D.V.M. (Age 60)M.B.A., Ph.D., Founder, Senior VP & Chief Scientific Officer Dr. Marc Bonneville Ph.D. (Age 64)Founder Mr. Jean Jacques Fournié Ph.D.FounderMr. Alessandro Moretta M.D.Ph.D., FounderMr. Frederic Lombard M.B.A. (Age 49)Senior VP & CFO Dr. Sonia Quaratino M.D. (Age 57)Ph.D., Executive VP, Chief Medical Officer & Member of Executive Board Mr. Arvind SoodExecutive VP, President of US Operations & Member of Executive BoardMore ExecutivesKey CompetitorsX4 PharmaceuticalsNASDAQ:XFORCentury TherapeuticsNASDAQ:IPSCZura BioNASDAQ:ZURAAcumen PharmaceuticalsNASDAQ:ABOSCardiff OncologyNASDAQ:CRDFView All CompetitorsInstitutional OwnershipOptiver Holding B.V.Sold 167,514 shares on 2/13/2024Ownership: 0.028%View All Institutional Transactions IPHA Stock Analysis - Frequently Asked Questions Should I buy or sell Innate Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IPHA shares. View IPHA analyst ratings or view top-rated stocks. What is Innate Pharma's stock price target for 2024? 1 brokerages have issued 12 month price objectives for Innate Pharma's shares. Their IPHA share price targets range from $8.00 to $11.50. On average, they predict the company's share price to reach $9.75 in the next twelve months. This suggests a possible upside of 301.2% from the stock's current price. View analysts price targets for IPHA or view top-rated stocks among Wall Street analysts. How have IPHA shares performed in 2024? Innate Pharma's stock was trading at $2.80 at the start of the year. Since then, IPHA stock has decreased by 13.2% and is now trading at $2.43. View the best growth stocks for 2024 here. Are investors shorting Innate Pharma? Innate Pharma saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 81,300 shares, an increase of 5.7% from the March 31st total of 76,900 shares. Based on an average daily trading volume, of 10,400 shares, the short-interest ratio is currently 7.8 days. View Innate Pharma's Short Interest. What ETFs hold Innate Pharma's stock? ETFs with the largest weight of Innate Pharma (NASDAQ:IPHA) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). What is Hervé Brailly's approval rating as Innate Pharma's CEO? 4 employees have rated Innate Pharma Chief Executive Officer Hervé Brailly on Glassdoor.com. Hervé Brailly has an approval rating of 100% among the company's employees. This puts Hervé Brailly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Innate Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (cdtx), VBI Vaccines (VBIV), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), INmune Bio (INMB), Pluristem Therapeutics (PSTI) and When did Innate Pharma IPO? Innate Pharma (IPHA) raised $80 million in an initial public offering (IPO) on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Innate Pharma? Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IPHA) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.